Clinical Trial: ROTATEQ™ Post-Marketing Surveillance in the Philippines

Study Status: Terminated
Recruit Status: Terminated
Study Type: Observational

Official Title: Protocol for ROTATEQ™ Post-Marketing Surveillance

Brief Summary: This study will collect demographic and safety information on the use of ROTATEQ™ in the Philippines.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Number of participants with adverse events following administration of ROTATEQ™ [ Time Frame: Three-year period following vaccine marketing approval (August 2007 to August 2010) ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: May 18, 2011
Date Started: October 2007
Date Completion:
Last Updated: October 29, 2015
Last Verified: October 2015